前列腺癌IMRT整合同步推量长期结局的前瞻性试验
10年生化控制率全队列85%,低、中、高危分别为84%、84%、90%;与未用SIB的历史队列相比5年和10年生化控制率更优(P=.02),且未增加毒性。
要点
- 全前列腺75.6 Gy/42次,ProstaScint高摄取区SIB至82 Gy,方案可行。
- 10年生化控制率全队列85%,低、中、高危分别为84%、84%、90%。
- SIB组5年和10年生化控制率94%和85%,优于无SIB队列的86%和61%(P=.02)。
核心结论
- 整合多模态影像的IMRT策略可行,SIB与更好的生化控制相关且未增加毒性。
研究设计与样本
- 全前列腺IMRT 75.6 Gy/42次,ProstaScint摄取增高区SIB至82 Gy。
- 中危和高危患者分别接受6个月和12个月辅助激素治疗。
- 与302例未用SIB、中位随访91个月(范围6-138个月)的相似治疗队列比较。
主要发现
- 中位随访120个月(范围24-150个月),10年生化控制率全队列85%,低、中、高危分别为84%、84%、90%。
- 全队列10年生存率69%。
- 治疗前PSA>10 ng/mL和推量体积>前列腺体积10%与更差的生化控制和生存显著相关。
- SIB组5年和10年生化控制率分别为94%和85%,无SIB队列分别为86%和61%(P=.02)。
- 接受SIB的队列未增加毒性。
临床怎么用
- 可基于多模态影像对前列腺内高摄取区行SIB至82 Gy,同时全前列腺75.6 Gy/42次。
- 治疗前PSA>10 ng/mL或推量体积>前列腺体积10%者预后较差,需加强关注。
局限性
- 与历史队列比较而非随机对照,存在混杂可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This report describes the long-term outcomes of a prospective trial of intensity modulated radiation therapy (IMRT), integrating a 111In capromab pendetide (ProstaScint) scan-directed simultaneous integrated boost (SIB) for localized prostate cancer. METHODS AND MATERIALS: Seventy-one patients with T1N0M0 to T4N0M0 prostate cancer were enrolled, and their ProstaScint and pelvic computed tomography scans were coregistered for treatment planning. The entire prostate received 75.6 Gy in 42 fractions with IMRT, whereas regions of increased uptake on ProstaScint scans received 82 Gy as an SIB. Patients with intermediate- and high-risk disease also received 6 months and 12 months of adjuvant hormonal therapy, respectively. RESULTS: The study enrolled 31 low-, 30 intermediate-, and 10 high-risk patients. The median follow-up was 120 months (range, 24-150 months). The 10-year biochemical control rates were 85% for the entire cohort and 84%, 84%, and 90% for patients with low-, intermediate-, and high-risk disease, respectively. The 10-year survival rate of the entire cohort was 69%. Pretreatment prostate-specific antigen level >10 ng/mL and boost volume of >10% of the prostate volume were significantly associated with poorer biochemical control and survival. The outcomes were compared with those of a cohort of 302 patients treated similarly but without the SIB and followed up for a median of 91 months (range, 6-138 months). The 5- and 10-year biochemical control rates were 86% and 61%, respectively, in patients without the SIB compared with 94% and 85%, respectively, in patients in this trial who received the SIB (P=.02). The cohort that received an SIB did not have increased toxicity. CONCLUSIONS: The described IMRT strategy, integrating multiple imaging modalities to administer 75.6 Gy to the entire prostate with a boost dose of 82 Gy, was feasible. The addition of the SIB was associated with greater biochemical control but not toxicity. Modern imaging technology can be used to locally intensify the dose to tumors and spare normal tissues, producing very favorable long-term biochemical disease control.
引用
- Schild MH, Schild SE, Wong WW, et al. A Prospective Trial of Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for Prostate Cancer: Long-term Outcomes Compared With Standard Image Guided IMRT. Int J Radiat Oncol Biol Phys. 2017. PMID: 28332984. doi:10.1016/j.ijrobp.2017.01.219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。